SCHEMBL4886788

SCHEMBL4886788

CCCCC[CH]c1ccccc1Br

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.38
HSD11B1 P28845 3/20 0.36
CCR3 P51677 1/20 0.34
TSHR P16473 1/20 0.33
SOAT2 O75908 1/20 0.33
SOAT1 P35610 1/20 0.33
CYSLTR2 Q9NS75 2/20 0.33
CYSLTR1 Q9Y271 2/20 0.33
CHRNA7 P36544 1/20 0.33
IKBKB O14920 1/20 0.33
DYRK2 Q92630 1/20 0.33
ALDH1A1 P00352 1/20 0.32
FAAH O00519 1/20 0.32
EPHX2 P34913 1/20 0.32
KMT2A Q03164 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889340 0.94 HSD11B1 (0.37) RECQLHSD11B1CCR3TSHRCHRNA7
SCHEMBL4897157 0.86 HSD11B1 (0.39) HSD11B1TSHRCHRNA7IKBKBDYRK2
SCHEMBL9559869 0.80 CYSLTR2 (0.47) RECQLHSD11B1SOAT2SOAT1CYSLTR2
SCHEMBL9559868 0.80 CYSLTR2 (0.47) RECQLHSD11B1SOAT2SOAT1CYSLTR2
SCHEMBL9834665 0.80 CYSLTR2 (0.47) RECQLHSD11B1SOAT2SOAT1CYSLTR2
SCHEMBL10651322 0.80 CYSLTR2 (0.47) RECQLHSD11B1SOAT2SOAT1CYSLTR2
SCHEMBL8496315 0.80 CYSLTR2 (0.47) RECQLHSD11B1SOAT2SOAT1CYSLTR2
SCHEMBL10383727 0.80 CYSLTR2 (0.47) RECQLHSD11B1SOAT2SOAT1CYSLTR2
SCHEMBL10383726 0.80 CYSLTR2 (0.47) RECQLHSD11B1SOAT2SOAT1CYSLTR2
SCHEMBL10651318 0.80 CYSLTR2 (0.47) RECQLHSD11B1SOAT2SOAT1CYSLTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194590-A1 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC 2008-08-14 US disclosed
EP-1869051-A1 4-PIPERAZINYLTHIENO Ý2,3-D¨PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2007-12-26 EP disclosed
WO-2006103545-A1 4-PIPERAZINYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194590-A1 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors PFKP, PF4, P2RY4 RECQL 107/4885HSD11B1 4805/4885CCR3 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.